宜明昂科-B（01541）今日盘中大涨19.52%，引发市场广泛关注。截至发稿时，该股报6.93港元，成交额2546.88万港元。
此次股价大涨主要受三方面利好消息推动。首先，公司发布的年度业绩报告显示，全年总收入达7,415万元，同比增长192倍，主要来自授权许可费和合作开发收入。其次，公司首席执行官田文志增持15万股H股，占公司已发行股份总数的约0.04%，表明管理层对公司未来发展充满信心。最后，国元国际发布的研报指出，基于公司CD47核心产品的领先优势，以及在多个适应症上的优秀疗效数据和安全性，该产品在肿瘤及自免领域市场空间广阔。
国元国际还强调，宜明昂科-B目前市值仅为22亿港元，账上现金有7.4亿人民币，加上潜在的BD收入，公司资金充足，足以支持研发推进。分析师认为，公司目前价值被严重低估，建议投资者积极关注。随着公司业绩的持续改善和市场认可度的提升，宜明昂科-B的股价有望继续走强。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.